Bavarian Nordic

Legal Proceedings Report • Jan 22, 2020

Bavarian Nordic’s Sale of Priority Review Voucher Receives Antitrust Clearance

Bavarian Nordic’s Sale of Priority Review Voucher Receives Antitrust Clearance

COPENHAGEN, Denmark, January 22, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the sale of its Priority Review Voucher (PRV) has received antitrust clearance. The transaction, which was announced on December 17, 2019 will now proceed towards closing, expected by end of January 2020.

For more information about the PRV sale, see company announcement no. 27/2019.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit www.bavarian-nordic.com.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Graham Morrell, Paddock Circle Advisors (US)

graham@paddockcircle.com

Tel: +1 781 686 9600

Company Announcement no. 03 / 2020

Attachment

• 2020-03-en